PMC Links for Books (Select 5581478) - PMC

Result Filters

Links from Books

Items: 2

Select item 88105771.

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma

Elaine Chang, Chana Weinstock, Lijun Zhang, Mallorie H. Fiero, Miao Zhao, Eias Zahalka, Tiffany K. Ricks, Jeanne Fourie Zirkelbach, Junshan Qiu, Jingyu Yu, Xiao Hong Chen, Vishal Bhatnagar, Kirsten B. Goldberg, Shenghui Tang, Paul G. Kluetz, Richard Pazdur, Amna Ibrahim, Julia A. Beaver, Laleh Amiri-Kordestani

Clin Cancer Res. Author manuscript; available in PMC 2022 Aug 1.

Published in final edited form as: Clin Cancer Res. 2022 Feb 1; 28(3): 441–445. Published online 2021 Aug 20. doi: 10.1158/1078-0432.CCR-21-2334

PMCID:: PMC8810577

Abstract Article PDF–393K

Select item 55696772.

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Robert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Oleg Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Harza, Mikhail Kogan, Boris Y. Alekseev, Cora N. Sternberg, Cezary Szczylik, David Cella, Cristina Ivanescu, Andrew Krivoshik, Andrew Strahs, Brooke Esteves, Anna Berkenblit, Thomas E. Hutson

J Clin Oncol. 2013 Oct 20; 31(30): 3791–3799. Published online 2013 Sep 9. doi: 10.1200/JCO.2012.47.4940